Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43244   clinical trials with a EudraCT protocol, of which   7156   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-005131-40
    Sponsor's Protocol Code Number:MA29957
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2016-09-09
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2015-005131-40
    A.3Full title of the trial
    A PHASE IIb, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF SILDENAFIL ADDED TO PIRFENIDONE IN PATIENTS WITH ADVANCED IDIOPATHIC PULMONARY FIBROSIS AND INTERMEDIATE OR HIGH PROBABILITY OF GROUP 3 PULMONARY HYPERTENSION.
    ESTUDIO DE FASE IIb MULTICÉNTRICO, DOBLE CIEGO,
    RANDOMIZADO, CONTROLADO CON PLACEBO PARA
    EVALUAR LA EFICACIA, SEGURIDAD Y TOLERANCIA DE
    SILDENAFILO EN COMBINACIÓN CON PIRFENIDONA EN
    PACIENTES CON FIBROSIS PULMONAR IDIOPATICA
    AVANZADA Y PROBABILIDAD INTERMEDIA O ALTA DE
    DESARROLLAR HIPERTENSIÓN PULMONAR GRUPO 3
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Study to Evaluate the Efficacy, Safety, and Tolerability of Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis and Intermediate or High Probability of Pulmonary Hypertension due to the lung disease.
    Un estudio para evaluar la eficacia, seguridad y tolerabilidad de Sildenafil Añadido a la pirfenidona en pacientes con fibrosis pulmonar idiopática avanzada e intermedia o alta probabilidad de hipertensión pulmonar debido a la enfermedad pulmonar.
    A.4.1Sponsor's protocol code numberMA29957
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorF. Hoffmann-La Roche Ltd
    B.1.3.4CountrySwitzerland
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportF. Hoffmann-La Roche Ltd.
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationF. Hoffmann-La Roche Ltd.
    B.5.2Functional name of contact pointTrial Information Support Line-TISL
    B.5.3 Address:
    B.5.3.1Street AddressGrenzacherstrasse 124
    B.5.3.2Town/ cityBasel
    B.5.3.3Post code4070
    B.5.3.4CountrySwitzerland
    B.5.4Telephone number34913257300
    B.5.6E-mailglobal.rochegenentechtrials@roche.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Esbriet
    D.2.1.1.2Name of the Marketing Authorisation holderRoche Registration Limited
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/04/241
    D.3 Description of the IMP
    D.3.1Product nameEsbriet
    D.3.2Product code RO0220912
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPIRFENIDONE
    D.3.9.1CAS number 53179-13-8
    D.3.9.2Current sponsor codeRO0220912
    D.3.9.4EV Substance CodeSUB09907MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number267
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Sildenafil
    D.2.1.1.2Name of the Marketing Authorisation holderTeva Pharmaceuticals USA Inc
    D.2.1.2Country which granted the Marketing AuthorisationUnited States
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameSildenafil
    D.3.2Product code RO0280296
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNSILDENAFIL
    D.3.9.1CAS number 139755-83-2
    D.3.9.4EV Substance CodeSUB10517MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    "Pulmonary Hypertension in patients with Idiopathic pulmonary fibrosis (IPF)
    "Hipertensión pulmonar en pacientes con fibrosis pulmonar idiopática (FPI)"
    E.1.1.1Medical condition in easily understood language
    Idiopathic pulmonary fibrosis leads to formation of scars in lungs due to unknown reason causing breathing problems. Pulmonary Hypertension is a disease adversely affecting blood flow in lungs.
    La fibrosis pulmonar idiopática conduce a la formación de cicatrices en los pulmones debido a la razón que causa problemas respiratorios desconocidos.
    E.1.1.2Therapeutic area Diseases [C] - Respiratory Tract Diseases [C08]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.0
    E.1.2Level PT
    E.1.2Classification code 10021240
    E.1.2Term Idiopathic pulmonary fibrosis
    E.1.2System Organ Class 10038738 - Respiratory, thoracic and mediastinal disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the efficacy of adding sildenafil compared with placebo to pirfenidone treatment in patients with advanced IPF and intermediate or high probability of Group 3 pulmonary hypertension (PH) on the basis of relevant decline in 6-minute walk distance (6MWD) of at least 15% from baseline, respiratory-related non-elective hospitalizations, or all-cause mortality
    El objetivo principal de eficacia de este estudio es evaluar la eficacia de sildenafilo,
    comparado con placebo, cuando se administra en combinación con pirfenidona en pacientes
    con FPI avanzada y probabilidad intermedia o alta de desarrollar HP grupo 3 en base a la Reducción relevante de la distancia recorrida en 6 minutos (6MWD) de al menos un 15% respecto al valor basal, hospitalización no programada
    por causas respiratorias o mortalidad
    E.2.2Secondary objectives of the trial
    •To evaluate the efficacy of adding sildenafil compared with placebo to pirfenidone treatment on the basis of
    Progression-free survival (PFS)
    Proportion of patients with decline in 6MWD of >=15% from baseline
    Time to all-cause and respiratory-related non-elective hospitalization
    Time to death from any cause and respiratory-related death
    Lung transplantation
    Change from baseline in transthoracic echocardiography (ECHO) parameters, pulmonary function tests (PFTs), and oxyhemoglobin saturation (SpO2) at rest and during the 6MWT
    World Health Organization (WHO) Functional Class
    Dyspnoea (assessed by the University of California San Diego Shortness of Breath questionnaire [UCSD SOBQ])
    Health-related quality of life (HRQoL) (assessed by the Saint George’s Respiratory Questionnaire [SGRQ])
    N-terminal pro-brain natriuretic peptide (NT-proBNP) level (assessed by a blood test)
    Evaluar eficacia de sildenafilo, comp. con placebo, cuando se administra en combinación con pirfenidona basándose en Supervivencia libre de progresión (SLP), definida como el t transcurrido hasta que se observa una reducción ≥15% en la 6MWD, en comp. con valor basal
    T transcurrido hasta la hospitalización no programada por causas respiratorias
    T transcurrido hasta la muerte por cualquier causa
    Trasplante pulmonar
    Cambio en parámetros de ecocardiograma transtorácico (ECO), pruebas de función pulmonar (PFP), saturación de oxihemoglobina (SpO2) en
    reposo y durante prueba de marcha de 6 minutos (6MWT)
    Clase funcional de la Organización Mundial de la Salud (OMS)
    Disnea (evaluada segun cuestionario de la Universidad de San Diego,
    California – UCSD SOBQ)
    Calidad de vida relacionada con la salud (CVRS) (evaluada basándose en el cuestionario de Saint George’s Respiratory Questionnaire [SGRQ])
    Nivel de prohormona N-terminal del péptido natriurético cerebral (NT-proBNP)
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    - Age 40-80 years (inclusive) at Screening
    - Diagnosis of IPF for at least 3 months prior to screening
    - Confirmation of IPF diagnosis by the Investigator, in accordance with the 2011 international consensus guidelines, at Screening
    - Advanced IPF as defined by a measurable carbon monoxide diffusing capacity/pulmonary diffusing capacity [DLCO] <= 40% of predicted value at Screening and intermediate or high probability of Grade 3 PH (as defined in the protocol)
    - Prior to the start of Screening, receiving pirfenidone for at least 12 weeks, and on a dose in the range of 1602 to 2403 mg/day for at least 4 weeks prior to the first Screening Visit.
    - WHO Functional Class II or III at Screening
    - 6MWD of 100 to 450 meters at Screening
    - For women of childbearing potential: agreement to remain abstinent or use a non-hormonal contraceptive method with a failure rate of <1% per year during the treatment period and for at least 58 days after the last dose of study treatment
    - For men who are not surgically sterile: agreement to remain abstinent or use contraceptive measures, and agreement to refrain from donating sperm for at least 118 days after the last dose of study treatment
    Tener entre 40 y 80 años de edad (ambos inclusive) en el período de selección
    FPI diagnosticada, como mínimo, 3 meses antes del período de selección
    En el período de selección diagnóstico de FPI confirmado por el investigador, de acuerdo con las directrices de consenso internacional de 2011
    FPI avanzada, definida por una DLCO medible ≤40% del valor previsto en el
    período de selección y probabilidad intermedia o alta de desarrollar HP grado 3 (según se ha definido más arriba en el apartado correspondiente a diseño del estudio)
    Antes de iniciar el período de selección, los pacientes deberán estar recibiendo
    pirfenidona desde hace al menos 12 semanas y la dosis se debe haber mantenido en el rango de 1602 a 2403 mg/día, como mínimo, 4 semanas antes de la primera visita de selección. Durante este período de 4 semanas
    pertenecer a la clase funcional II o III de la OMS en el período de selección
    6MWD de 100 a 450 metros en el período de selección
    Las mujeres potencialmente fértiles deben comprometerse a practicar la abstinencia
    sexual (es decir, abstenerse de mantener relaciones heterosexuales) o a utilizar un
    método anticonceptivo no hormonal que tenga una tasa de fallos <1% al año, durante el
    período de tratamiento y como mínimo hasta 58 días después de la administración de la última dosis del tratamiento del estudio
    Los varones que no estén esterilizados quirúrgicamente deben comprometerse a practicar la abstinencia sexual o a utilizar métodos anticonceptivos, así como abstenerse de donar semen como mínimo hasta 118 días después de la administración de la última dosis del fármaco
    E.4Principal exclusion criteria
    - History of any of the following types of PH: Group 1 pulmonary arterial hypertension (PAH); Group 2 (left-heart disease); Group 3 (due to conditions other than interstitial lung disease; Group 4 (chronic thromboembolic pulmonary hypertension); Group 5 (other disorders)
    - History of clinically significant cardiac disease in the opinion of the Investigator
    - History of coexistent and clinically significant (in the opinion of the Investigator) COPD, bronchiectasis, asthma, inadequately treated sleep-disordered breathing, or any clinically significant pulmonary diseases or disorders other than IPF or PH secondary to IPF
    - Hypotension, autonomic dysfunction, or conditions in which vasodilation may cause an unsafe drop in blood pressure (BP)
    - History of use of drugs and toxins known to cause PAH
    Antecedentes de cualquiera de los tipos siguientes de HP: Grupo 1 (hipertensión arterial pulmonar [HAP]); grupo 1 (enfermedad venooclusiva pulmonar y/o hemangiomatosis capilar pulmonar); grupo 2 (cardiopatía izquierda); grupo 3 (debida a trastornos distintos de enfermedad pulmonar intersticial); grupo 4 (hipertensión pulmonar tromboembólica crónica); grupo 5 (otros trastornos)
    Antecedentes de cardiopatías clínicamente significativas, de acuerdo con la opinión del investigador
    Antecedentes de afecciones pulmonares concurrentes y clínicamente significativas (de acuerdo con la opinión del investigador), tales como EPOC (incluyendo bronquitis crónica, enfisema), bronquiectasis, asma, trastorno respiratorio del sueño no tratado
    adecuadamente o cualquier enfermedad o trastorno pulmonar clínicamente significativo distinto de FPI o HP secundaria a FPI
    Hipotensión, disfunción autonómica o trastornos en los que la vasodilatación pueda causar un descenso peligroso de la PA
    Uso previo de fármacos y toxinas conocidos por causar HAP
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy endpoint will be evaluated based on a comparison of the proportion of patients showing disease progression over 52 weeks of treatment period, as evidenced by reaching the following combined endpoint:
    •Relative decline in 6MWD of at least 15% from baseline (as defined in the protocol), respiratory related non elective hospitalization, or all cause mortality
    La variable principal se evaluará basándose en la comparación
    de la proporción de pacientes que muestran progresión de la enfermedad durante el período de tratamiento de 52 semanas, lo que se evidenciará si se alcanza el objetivo combinado siguiente:
    - Reducción relevante de la 6MWD de al menos un 15% respecto al valor basal (según se
    define en el protocolo), hospitalizaciónno programada por causas respiratorias o
    mortalidad por todas las causas
    E.5.1.1Timepoint(s) of evaluation of this end point
    •The primary analysis of the study will be conducted when all patients completed the 52 weeks treatment phase and the mandatory 4 weeks follow-up visit.
    • Se llevará a cabo el análisis principal del estudio, cuando todos los pacientes completaron la fase de 52 semanas de tratamiento y las 4 semanas obligatorias de visita de seguimiento.
    E.5.2Secondary end point(s)
    Efficacy:
    1.Progression-free survival (PFS)
    2.Proportion of patients with decline in 6MWD of >=15% from baseline
    3.Time to respiratory-related non-elective hospitalization
    4.Time to death from any cause
    5.Lung transplantation will be analysed descriptively
    6.Time to all-cause non-elective hospitalization
    7.Time to respiratory-related death
    8.Change from baseline in transthoracic ECHO parameters
    9.Change from baseline in PFTs (FVC, FEV1, FEV1/FVC, and DLCO)
    10.Oxyhemoglobin saturation (SpO2) at rest and during the 6MWT will be summarized descriptively over time
    11.Borg scale measurement of perceived exertion will be summarized descriptively over time
    12.WHO Functional Class II or III over time
    13.Dyspnea as assessed by UCSD SOBQ will be summarized descriptively over time
    14.HRQoL (assessed by SGRQ) will be summarized descriptively over time
    15.Changes from baseline in NT-proBNP levels
    Safety:
    16.Nature, frequency, severity, relationship and timing of treatment-emergent adverse events
    17.Changes in vital signs, physical examination, clinical laboratory test results, 12-lead electrocardiograms (ECGs)
    18.Proportion of patients with study discontinuation or study drug discontinuation
    Eficacia:
    1. Supervivencia libre de progresión (SLP)
    2. Proporción de pacientes que muestran una reducción ≥15% en la 6MWD respecto al valor basal
    3. Tiempo transcurrido hasta la hospitalización no programada por causas respiratorias
    4. Tiempo transcurrido hasta la muerte por cualquier causa
    5. Trasplante pulmonar
    6. Tiempo transcurrido hasta la hospitalización no programada por todas las causas
    7. Tiempo transcurrido hasta la muerte por causas respiratorias
    8. Cambio en los parámetros del ecocardiograma transtorácico (ECO) respecto al valor basal
    9. Cambio respecto al valor basal en pruebas de función pulmonar en PFP, (FVC, FEV1, FEV1/FVC, y DLCO)
    10. saturación de oxihemoglobina (SpO2) en reposo y durante la prueba de marcha de 6 minutos (6MWT)
    11. Empeoramiento de la intensidad máxima en la escala de Borg sumarizada descriptivamente a lo largo del tiempo
    12. Clase funcional II o III de la OMS a lo largo del tiempo
    13. Disnea evaluada según UCSD SOBQ sumarizada descriptivamente a lo largo del tiempo
    14. Calidad de vida relacionada con la salud (CVRS) evaluada según SGRQ sumarizada descriptivamente a lo largo del tiempo
    15. Cambios respecto del nivel basal en niveles de prohormona N-terminal del péptido natriurético cerebral (NT-proBNP)
    16. Características, incidencia, severidad, relación y momento de aparición de los acontecimientos adversos originados por el tratamiento
    17. Cambios en las constantes vitales, hallazgos en la exploración física, resultados de las pruebas de laboratorio clínico, electrocardiogramas de 12 derivaciones (ECG)
    18. Terminación prematura del estudio o del tratamiento con los fármacos del estudio
    E.5.2.1Timepoint(s) of evaluation of this end point
    1-18. The primary analysis of the study will be conducted when all patients completed the 52 weeks treatment phase and the mandatory 4 weeks follow-up visit.
    1-18. Se llevará a cabo el análisis primario del estudio, cuando todos los pacientes completaron la fase de 52 semanas de tratamiento y el 4 semanas obligatorias visita de seguimiento.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    TOLERABILITY
    TOLERABILIDAD
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA41
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Belgium
    Canada
    Czech Republic
    Egypt
    Germany
    Greece
    Hungary
    Israel
    Italy
    Netherlands
    South Africa
    Spain
    Turkey
    United Arab Emirates
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the clinical trial is defined as the date when the last patient completes the last visit (LPLV) or the date at which the last data point which is required for the statistical analysis is received, whichever is the later date.
    La terminación del estudio clínico se define como la fecha en la que el último paciente completa la última visita (UVUP) o la fecha en la que se reciben los últimos datos requeridos para el análisis estadístico, dependiendo de la que sea posterior.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years
    E.8.9.1In the Member State concerned months40
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months3
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 44
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 132
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state9
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 117
    F.4.2.2In the whole clinical trial 176
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    The sponsor will offer the possibility to the patient to receive pirfenidone within the study protocol for 12 months safety FU after completing visit 10. Following this period, the Sponsor will offer post-trial access to pirfenidone free of charge to eligible patients in accordance with the Roche Global Policy on Continued Access to Investigational Medicinal Product (please see protocol section 4.3.4).
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-10-20
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-10-06
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2023 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA